Galapagos’ bowel drug misses the mark in Phase II

Damian Garde Belgian biotech Galapagos is shutting down an ulcerative colitis program after its top prospect failed to make a difference in a Phase II trial, putting off plans for late-stage ...

Syros raises $40M to get its leukemia drug into Phase II

Damian Garde Syros Pharmaceuticals raised $ 40 million in equity to push forward with its pipeline of genetically targeted drugs, securing the cash it needs to take its top prospect ...

Adamas soars as its Parkinson’s drug comes through in Phase III

Damian Garde Adamas Pharmaceuticals' lead drug met its main goals of reducing side effects related to Parkinson's disease treatment in a late-stage trial, the company said, ...

Kamada’s rabies treatment clears Phase III with an FDA app on deck

Damian Garde Kamada's immunoglobulin treatment for rabies met its main goal in a late-stage trial, clearing the way for an FDA application next year. FierceBiotech News

Novartis keeps its CAR-T lead with positive Phase II data

Damian Garde Novartis, leading a pack of companies developing genetically engineered T cells to fight cancer, unveiled more promising data on its Phase II treatment as it wends toward ...

Isis and GlaxoSmithKline eye Phase III with a rare disease drug

Damian Garde GlaxoSmithKline and partner Isis Pharmaceuticals are plotting a pivotal trial in the rare TTR amyloid cardiomyopathy, an inherited disease that impairs the heart muscle. FierceBiotech ...

Cempra tanks on ‘positive’ Phase III for pneumonia antibiotic

Damian Garde Cempra's in-development treatment for bacterial pneumonia measured up to the now-generic antibiotic moxifloxacin in a Phase III study, but the combination of alarming ...

UPDATED: Melinta’s CEO steps down amid a big Phase III push

Damian Garde Melinta Therapeutics CEO Mary Szela has left the company in the middle of a late-stage program for its lead antibiotic, a move that comes just months after the biotech ...

Geron jumps as its J&J-partnered cancer drug shows promise in Phase II

Damian Garde Long-troubled drug developer Geron is touting what it calls "unprecedented" early results for its lead cancer drug, sending the biotech's share price up as ...

Avalanche hits the brakes on its gene therapy program after a Phase II misstep

Damian Garde Avalanche Biotechnologies, months removed from a costly Phase II dud, is calling off plans for further study of its lead gene therapy candidate, heading back to the lab ...

Big Pharma pushes new migraine drugs into Phase III with blockbuster hopes

Damian Garde A cadre of drugmakers is pressing toward late-stage trials with new injectable treatments in the long-stagnant field of migraine therapy, racing to capitalize on what analysts ...

Aquinox’s bladder pain drug misses the mark in Phase II

Damian Garde Aquinox's lead drug failed its main goal in a Phase II trial on bladder pain syndrome, but the company believes its oral treatment showed enough to promise to merit ...
Page 1 of 1112345...10...Last »
© 2017 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS